INO..$.66. It has an impressive pipeline consisting of seven products in phase I or II and two in pre-clinical. These address prostate cancer, hepatitis C, HIV, influenza, malaria and tropical diseases. Importantly, its lead product, VGX-3100 for cervical cancer, will report out topline data from a phase II trial in 2H, 2013.
This year could be the coming out party for Inovio. Maxim Group starts at BUY.